25. Progressive multifocal leukoencephalopathy Clinical trials / Disease details
Clinical trials : 26 / Drugs : 35 - (DrugBank : 22) / Drug target genes : 8 - Drug target pathways : 37
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000022151 | 2016/04/30 | 30/04/2016 | The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathy | The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathy - The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathy | The efficacy and safety of mefloquine in patients with progressive multifocal leukoencephalopathy | mefloquine is to be taken orally 275mg for 3days then 275mg weekly for 6 manths | Department of Neurology, Shimane University Hospital | NULL | Complete: follow-up complete | 20years-old | Not applicable | Male and Female | 5 | Not selected | Japan |
| 2 | JPRN-UMIN000023752 | 2016/04/14 | 24/08/2016 | Medication with mefloquine hydrochloride for progressive multifocal leukoencephalopathy (PML) out of the application range of insurance | Medication with mefloquine hydrochloride for progressive multifocal leukoencephalopathy (PML) out of the application range of insurance - Medication with mefloquine hydrochloride for progressive multifocal leukoencephalopathy (PML) out of the application range of insurance | progressive multifocal leukoencephalopathy | Oral mefloquine hydrochloride 275mg once a day at first 3 days. Since second week, 275mg in each week oral intake until 6 months | Nagoya City University | NULL | Complete: follow-up complete | Not applicable | Not applicable | Male and Female | 1 | Not applicable | Japan |
| 3 | EUCTR2008-001314-24-IT (EUCTR) | 15/01/2009 | 19/03/2009 | A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) - ND | A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) - ND | Progressive Multifocal Leukoencephalopathy (PML) MedDRA version: 9.1;Level: LLT;Classification code 10036807;Term: Progressive multifocal leukoencephalopathy | Trade Name: Lariam INN or Proposed INN: Mefloquine | BIOGEN IDEC LTD | NULL | Not Recruiting | Female: yes Male: yes | 40 | United Kingdom;France;Spain;Italy | |||
| 4 | EUCTR2008-001314-24-GB (EUCTR) | 02/01/2009 | 28/05/2008 | A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) | A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) | Progressive Multifocal Leukoencephalopathy (PML) MedDRA version: 9.1;Level: LLT;Classification code 10036807;Term: Progressive multifocal leukoencephalopathy | Trade Name: Lariam Product Name: Mefloquine Product Code: 111JC101 INN or Proposed INN: MEFLOQUINE | Biogen Idec Ltd | NULL | Not Recruiting | Female: yes Male: yes | 60 | United Kingdom;France;Spain;Italy | |||
| 5 | NCT00746941 (ClinicalTrials.gov) | January 2009 | 3/9/2008 | Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML) | A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects With Progressive Multifocal Leukoencephalopathy (PML) | Progressive Multifocal Leukoencephalopathy | Drug: mefloquine | Biogen | Elan Pharmaceuticals | Terminated | 18 Years | 75 Years | All | 37 | Phase 1/Phase 2 | United States;Brazil;Germany;Italy;Spain;Australia;France;Puerto Rico;United Kingdom |
| 6 | EUCTR2008-001314-24-ES (EUCTR) | 19/11/2008 | 11/07/2008 | A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML)Estudio aleatorizado con evaluador en condiciones de ciego para explorar el efecto de mefloquina en sujetos con leucoencefalopatía multifocal progresiva (LMP) | A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML)Estudio aleatorizado con evaluador en condiciones de ciego para explorar el efecto de mefloquina en sujetos con leucoencefalopatía multifocal progresiva (LMP) | Progressive Multifocal Leukoencephalopathy (PML)Leucoencefalopatía Multifocal Progresiva (LMP) MedDRA version: 9.1;Level: LLT;Classification code 10036807;Term: Progressive multifocal leukoencephalopathy | Trade Name: Lariam Product Name: Mefloquine Product Code: 111JC101 INN or Proposed INN: MEFLOQUINE | Biogen Idec Ltd | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 2 | France;Spain;Italy;United Kingdom | ||
| 7 | EUCTR2008-001314-24-FR (EUCTR) | 22/10/2008 | 23/07/2008 | A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) | A Randomized, Rater-Blinded Study to Explore the Effect of Mefloquine in Subjects with Progressive Multifocal Leukoencephalopathy (PML) | Progressive Multifocal Leukoencephalopathy (PML) MedDRA version: 9.1;Level: LLT;Classification code 10036807;Term: Progressive multifocal leukoencephalopathy | Trade Name: Lariam Product Name: Mefloquine Product Code: 111JC101 INN or Proposed INN: MEFLOQUINE | Biogen Idec Ltd | NULL | Not Recruiting | Female: yes Male: yes | 40 | Phase 2 | France;Spain;Italy;United Kingdom |